  Over the past decade , therapies targeting the VEGF/VEGFR and mTOR pathways have served as the standard of care for the clinical management of renal cell carcinoma ( RCC) patients. Albeit promising , these targeted drugs have attained only modest clinical benefits with limited prolonged progression-free survival. Therefore , alternative reasonable and applicable therapeutic approaches should be introduced to improve the clinical outcome of RCC patients.